ArticleDrug design, development and therapy2026
A Dual-Function Gastroretentive System: Enhancing Ofloxacin Bioavailability via Floating-Bioadhesive Pellets Based on a Hollow Structure Prepared with a Hybrid Polymer Film.
Article in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: This study aimed to design and characterize a novel dual-function floating-bioadhesive drug delivery system based on a hollow structure to extend gastroretentive time and enhance the bioavailability of ofloxacin. Methods: Hollow spherical shells were fabricated via fluidized-bed coating using a blended polymer film composed of (SuE (Surelease Results: The blended film at a SuE/EuN ratio of 4:4 exhibited optimal mechanical rigidity and strength for the hollow shell. Analysis of the release profile showed a zero-order release for the first 4 h, which was in accordance with the predicted value. The optimized formulation demonstrated excellent buoyancy with a floating rate of 96.3±0.5% and 100% bioadhesion on gastric mucosa. In vivo pharmacokinetic studies in New Zealand rabbits revealed that the test formulation had a prolonged elimination half-life (6.65±0.94 h) and a relative bioavailability of 112.2±14.9% compared to the reference tablet. Conclusion: The developed floating-bioadhesive system successfully combined hollow-structure buoyancy with mucoadhesion to achieve prolonged gastric retention and sustained drug release, offering a feasible approach for gastroretentive drug delivery systems.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.